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ABSTRACT: Background. Squamous cell carcinoma of the head and
neck can present as a cervical metastasis from an unknown primary
site. The standard diagnostic workup includes panendoscopy and
directed biopsies but this will fail to identify a portion of unknown
primary tumors.
Methods. Herein, we present a case report of a male patient with an
unknown primary tumor in which the da Vinci surgical robot was used to
evaluate the tongue base.
Results. Clinical evaluation, imaging, and panendoscopy with directed
biopsies failed to detect the primary tumor site. Robot-assisted biopsy of
a broad area of the tongue base, incorporating submucosal tissue,
identified the primary tumor with minimal postoperative morbidity.
Conclusion. Failure to localize an unknown primary tumor often results
in widespread irradiation of the upper aerodigestive tract, inducing
significant morbidity. Robot-assisted biopsies of the tongue base may
identify unknown primaries that would otherwise have been missed
through standard directed biopsy techniques. VC 2011 Wiley Periodicals,
Inc. Head Neck 35: E126–E130, 2013
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Approximately 2% to 5% of squamous cell carcinomas of
the head and neck present as a cervical metastasis from
an unknown primary tumor site.1 Localization of the
unknown primary tumor remains a challenge, with fewer
than 60% of primary tumors eventually being discov-
ered.2 The primary site, when identified, is usually in the
upper aerodigestive tract, specifically the palatine tonsils,
base of tongue, and nasopharynx. Small tumors originat-
ing in these areas can be missed by clinical and radio-
graphic assessment due to the inherent anatomic com-
plexity of these regions and limitations of currently used
diagnostic techniques.3
To be designated as a true unknown primary tumor,
patients should undergo a comprehensive evaluation by an
experienced head and neck surgeon. The evaluation begins
with a thorough head and neck physical examination fol-
lowed by fiber-optic endoscopy of the nasopharynx, oro-
pharynx, hypopharynx, and larynx.1,2 Between 52% and
55% of unknown primaries are identified on the basis of
history and physical examination alone.2
Contrast-enhanced CT and/or MRI with gadolinium are
an integral component of the workup for the unknown
primary. Use of either modality will result in detection of
occult primary sites in 17% to 31% of cases.2,3 Positron
emission tomography (PET), either alone or fused with
CT imaging (PET-CT), has been advocated as an adjunc-
tive modality where CT and/or MRI fail to yield an appa-
rent primary site. A recent retrospective study demon-
strated that PET-CT has a detection rate of 36.8%, which
is higher than the PET detection rate of 25% averaged
from 16 studies.4 Although PET-CT demonstrates
improved specificity over PET (95% vs 75%), it remains
susceptible to false positives due to higher metabolism in
the lymphatic tissue of Waldeyer’s ring, including the
palatine and lingual tonsils.4
Panendoscopy is a critical component of the diagnostic
workup and remains the gold standard for the identifica-
tion of unknown primary tumors. Panendoscopy can
detect previously occult primary tumors in 16% to 26%
of cases.2 However, mucosal abnormalities suggestive of
malignancy are often not seen on panendoscopy leading
to the practice of ‘‘directed’’ biopsies in the nasopharynx,
tongue base, tonsils, and pyriform sinuses, even in the ab-
sence of a visual abnormality. In 1 series, 9% of occult
tumors were diagnosed on the basis of these random or
directed biopsies.2,5 The tongue base is the most common
site harboring unknown primary tumors.2 In contrast to
the tonsil, a complete biopsy of the entire base of tongue
is technically difficult with traditional instruments. As a
result, palpation of the tongue base and visualization of
subtle mucosal irregularities or areas of friability direct
biopsies toward focal areas of the tongue base.
We have recently used the da Vinci surgical robot (In-
tuitive Surgical, Sunnyvale, CA) to facilitate biopsies of
the tongue base in cases of an unknown primary tumor.
The enhanced access to the base of tongue allows us to
*Corresponding author: V. Divi, Department of Otolaryngology: Head and Neck
Surgery, University of Michigan, Ann Arbor, M ichigan 48109.
E-mail: vasudivi@med.umich.edu
E126 HEAD & NECK—DOI 10.1002/HED APRIL 2013
FIGURE 1. Discrete and fused positron emission tomography-CT (PET-CT) images demonstrate an enlarged, necrotic, right level II/III lymph node (4
 2.8  2.5 cm) with intensely increased fluorodeoxyglucose (FDG) uptake. Immediately posterior to this mass is a smaller, level IIb lymph node
with mild FDG avidity. The distribution of FDG in the remainder of the head and neck is within physiologic limits. In particular, no abnormal FDG
uptake is visualized in the tongue base.
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obtain a biopsy covering a greater mucosal surface area
without significant morbidity. This case report illustrates
this novel paradigm.
CASE REPORT
A 57-year-old man presented to our clinic for evaluation
of an asymptomatic right neck mass. The patient had a 30
pack-year smoking history but had quit 16 years earlier. He
had a tonsillectomy during childhood. The right neck mass
had been noticed 6 weeks before presentation and was
treated with several courses of antibiotics by outside physi-
cians. A CT scan requested by the referring otolaryngolo-
gist demonstrated a 4  2.8  2.5 cm mass in level II/III of
the right neck. Fine-needle aspiration of this mass demon-
strated metastatic squamous cell carcinoma. A PET scan
ordered by the outside surgeon showed a necrotic, intensely
fluorodeoxyglucose (FDG)-avid lymph node, correspond-
ing to the lesion seen on CT, and several smaller FDG-avid
level IIb nodes but no primary tumor (Figure 1). Our physi-
cal examination, including flexible laryngoscopy, failed to
yield a primary tumor site. Neck palpation did demonstrate
an obvious soft, mobile level II/III lymph node. The patient
was classified as having a TxN2bM0 squamous cell carci-
noma of the right neck.
The patient was taken to the operating room for panen-
doscopy and directed biopsies after providing written
informed consent. Palpation of the oropharynx revealed a
firm nodule in the right tongue base. On direct laryngos-
copy, a pale, raised area measuring approximately 5 mm
in diameter was seen in the inferior right tongue base,
corresponding to the previously palpated area. To better
define this site, microdirect laryngoscopy was performed
using suspension laryngoscopy and a 0 rigid endoscope
attached to a high definition video system. Precise biop-
sies of the seemingly abnormal area and additional biop-
sies in the surrounding mucosa and glossotonsillar sulcus
were taken and sent for frozen section biopsies. All the
biopsies were negative for malignancy. An unremarkable
esophagoscopy was then performed. Nasopharyngoscopy
was then performed using a rigid endoscope which
revealed no lesions. Frozen-section biopsies of the bilat-
eral nasopharynx were negative for malignancy. Given
the failure to elucidate the primary tumor site on panen-
doscopy, we proceeded with transoral robotic biopsy of
the right lingual tonsil. A Crowe–Davis mouth gag was
inserted and the patient was placed in suspension to opti-
mize tongue base visualization. The da Vinci robot was
positioned and the robotic arms placed transorally, as pre-
viously described.6 An incision was made perpendicular
to the midline to define the anterior extent of the biopsy,
just posterior to the circumvallate papillae. This incision
was continued to the midline where a longitudinal inci-
sion was made to define the medial border. This created
a tissue edge which was then retracted with the Maryland
dissector. A lateral cut was made just medial to the lat-
eral pharyngeal wall. Electrocautery was used to remove
the superficial portion of the lingual tonsil extending
from the circumvallate papillae to just proximal to the
vallecula. Once the mucosa was circumferentially
resected, it was oriented and passed off the field for per-
manent pathology. The patient’s neck disease was then
addressed with an uncomplicated selective neck dissec-
tion incorporating levels I to IV. The patient was extu-
bated at the end of the surgery and, after recovery in the
postoperative care unit, was transferred to the general
care floor.
Postoperatively, the patient did not demonstrate any
respiratory difficulties. He was advanced to a full liquid
diet on postoperative day 0 with no aspiration noted. He
was discharged home on postoperative day 2, returning
to the clinic on postoperative day 8 for follow-up. At
that time, he reported mild odynophagia and he was
advanced to a regular diet. He was diagnosed with oral
candidiasis and started on nystatin swish and swallow.
Pathologic analysis of the operative specimens con-
firmed that the traditional directed biopsies of the
tongue base and nasopharynx were negative for malig-
nancy. The right lingual tonsil resection, however, dem-
onstrated a focus of human papillomavirus–positive
invasive squamous cell carcinoma in the deep tissue at
the inferior/medial margin with no abnormality noted in
the overlying squamous mucosa (Figure 2). The right
neck dissection yielded 34 lymph nodes, of which a sin-
gle 3.2-cm level III lymph node, corresponding to the
patient’s neck mass, was positive for carcinoma with no
evidence of extracapsular extension. These results were
discussed at our multidisciplinary head and neck tumor
board, and the tumor was reclassified as pT1N2aM0.
Because the primary lesion was close to the midline
base of tongue, it was felt that the patient would need
treatment to the bilateral necks. While definitive resec-
tion of the central tongue base and contralateral neck
dissection remained an option, the tumor board recom-
mended radiation to the primary site and to the bilateral
necks as optimal treatment.
DISCUSSION
The treatment of the unknown primary tumor varies
between different institutions. The most commonly used
FIGURE 2. Hematoxylin-eosin staining of tongue base biopsy
(original magnification 100) demonstrating squamous cell
carcinoma in the bottom right with overlying normal tonsillar
tissue in the upper left of the main image. The inset represents
the identified squamous cell carcinoma (original magnification
400).
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strategies include upfront concurrent chemoradiation ver-
sus neck dissection followed by adjuvant radiation or che-
moradiation based on the pathology results. Identification
of an unknown primary tumor can significantly influence
patient treatment and side effects.
In patients with N1 and some N2a neck disease in
whom the primary tumor has been identified in the oro-
pharynx, treatment may allow for surgical extirpation of
the primary and neck dissection without adjuvant chemo-
therapy or radiation. In cases in which adverse pathologic
features are present, patients require adjuvant treatment.
However, the radiation doses are reduced and can be
focused on the primary tumor site, as opposed to covering
all potential primary sites. Those with more advanced
neck disease (N2/N3) and no evidence of extracapsular
spread can also be treated with unilateral comprehensive
neck dissection followed by bilateral neck irradiation and
targeted mucosal irradiation of the oropharynx. In these
patients, identifying the primary tumor and performing a
neck dissection again offers focused radiation and the
potential to avoid chemotherapy as part of their treatment.
Currently, up-front concurrent chemoradiation is an
increasingly used option even in these patients.7,8
The identification of an unknown primary tumor site
can potentially spare the patient the significant morbidity
associated with concurrent chemoradiation. In a recent
study investigating the treatment of unknown primaries of
the head and neck, the incidence of grade 3þ acute toxic-
ity (most commonly severe, confluent mucositis) was
59% among patients treated with chemoradiation versus
25% among those treated with radiation alone (p <
.001).8 The risk of grade 3þ acute esophagitis was also
significantly increased in the chemoradiation group relative
to the radiation therapy alone group (47% vs 21%; p <
.001). Late effects were also significantly higher in the che-
moradiation group versus the radiation alone group. These
late effects included dysphagia secondary to esophageal
toxicity (41% vs 11%; p < .001), esophageal structure
(34% vs 7%; p < .001), and gastrostomy tube dependence
at 1 year (16% vs 0%; p < .001). Nearly 20% of the
patients treated with concurrent chemoradiation required
hospitalization for acute renal failure, intractable nausea/
FIGURE 3. Proposed algorithm for management of the unknown head and neck primary incorporating transoral robotic biopsy of the tongue base
in cases where standard panendoscopy fails to yield a pathologic diagnosis. PET, positron emission tomography; NCCN, National Comprehensive
Cancer Network
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vomiting, and neutropenic fever, among other reasons,
compared to only 4% treated with radiation alone.8
Even in those institutions that elect to forego chemo-
therapy and instead use comprehensive radiation of mu-
cosal sites commonly harboring occult primary tumors
and the bilateral necks, the resultant toxicity can be
impressive. These toxicities include a high incidence of
xerostomia, mucositis, skin damage, dysphagia, and
stricture.2 More advanced intensity-modulated radiother-
apy (IMRT) regimens have improved upon the toxicity
of conventional radiotherapy but still induce significant
morbidity. In 1 study from Memorial Sloan–Kettering
Cancer Center, IMRT, when compared with conven-
tional radiotherapy, significantly reduced the risk of
grade 1 to 2 xerostomia (57% vs 43%, respectively)
and in gastrostomy rates (72% vs 43%, respectively).9
Nonetheless, these risks remain markedly higher than
those associated with IMRT directed to an identified
primary site and unilateral or bilateral necks. To illus-
trate, had the primary site not been identified in the
index case discussed above, the presence of N2 disease
would have resulted in comprehensive radiation of the
mucosal surfaces of the upper aerodigestive tract, the
nasopharynx or retropharyngeal nodes, and the bilateral
necks, with concurrent chemotherapy. Thus, techniques
that may facilitate the detection of the primary tumor
are particularly pertinent.
There is an increased incidence of human papillomavir-
us–associated oropharyngeal carcinoma located in the
tonsillar or base of tongue tissue, which tend to present
with larger neck disease and smaller primary tumors. If
this does lead to an increased incidence of unknown pri-
mary tumors, better evaluation of the base of tongue
would aid in localizing this disease. Transoral robotic sur-
gery allows for a superficial ‘‘pancake’’ biopsy incorpo-
rating the entirety of the suspected tongue base. This per-
mits pathologic analysis of a larger volume of tongue
base tissue, potentially enhancing the probability of
detecting the occult primary tumor. This may be of par-
ticular value in the scenario described in our index case
where standard biopsies via microdirect laryngoscopy
were negative or where a discrete abnormality is not
noted on routine endoscopy. Furthermore, as in the index
case, the primary site may be submucosal with histologi-
cally ‘‘normal’’ overlying squamous mucosa (Figure 2).
The controlled depth of the excisional biopsy limits func-
tional morbidity and abbreviates hospital stay, but allows
for pathologic evaluation of this submucosal disease.
We propose a novel algorithm for the workup of the
unknown primary tumor that incorporates use of the da
Vinci surgical platform (Figure 3). The initial preopera-
tive workup and imaging studies are essentially
unchanged from those described above. The patient is
then brought to the operating room for panendoscopy and
biopsies. The highest yield site for biopsies is the tongue
base, which is the most likely site harboring an unknown
primary tumor.3 Direct or microdirect laryngoscopy with
biopsies should be performed. If the intraoperative frozen
section is negative for malignancy, the da Vinci surgical
robot, in the context of our proposed algorithm, is used
for transoral tongue base biopsy, with excision of a wide
‘‘pancake’’ specimen. This specimen is sent for perma-
nent pathology. Additional biopsies are taken, as
indicated, from the nasopharynx and a tonsillectomy is
performed. A unilateral selective neck dissection may be
considered to provide lymph node tissue for evaluation of
metastasis and determination of extracapsular spread.
This will allow for treatment stratification per National
Comprehensive Cancer Network guidelines should the
primary tumor not be detected on the robotic tongue base
biopsy.
The detection of the primary site in cases of unknown
primaries of the head and neck is a management priority.
Use of the da Vinci robot to obtain a ‘‘pancake’’ biopsy
of the most common site of these occult primaries, the
tongue base, may facilitate detection of primary tumors
relative to standardly used panendoscopy techniques. The
key benefit derived from establishing the diagnosis is the
avoidance of wide radiation fields used for the treatment
of unknown primaries and the potential avoidance of con-
current chemotherapy. Clinical trials will need to be
designed to investigate the efficacy of transoral robotic
surgery tongue base biopsy in identifying the primary site
of disease in occult head and neck malignancies. Until
these definitive studies are performed, this technique
should be viewed as a management option, but should
not be considered standard of care.
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